Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

Y0001271

Aciclovir for peak identification 1

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Acycloguanosine, 9-[(2-Hydroxyethoxy)methyl]guanine, Acyclovir

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C8H11N5O3
Número CAS:
59277-89-3
Peso molecular:
225.20
Número MDL:
MFCD00057880
Código UNSPSC:
41116107
ID de substância PubChem:
329831334
NACRES:
NA.24

grau

pharmaceutical primary standard

descrição

API family: acyclovir

família API

acyclovir

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

NC1=Nc2c(ncn2COCCO)C(=O)N1

InChI

1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

chave InChI

MKUXAQIIEYXACX-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Aciclovir for peak identification 1 EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

A0220000

Aciclovir, European Pharmacopoeia (EP) Reference Standard

1012065

Acyclovir, United States Pharmacopeia (USP) Reference Standard

1012076

Acyclovir Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1254

Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001264

Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard

1012087

Acyclovir Related Compound G, United States Pharmacopeia (USP) Reference Standard

1012054

Acyclovir Related Compound F, United States Pharmacopeia (USP) Reference Standard

BP438

Aciclovir, British Pharmacopoeia (BP) Reference Standard

Y0002245

Aciclovir for system suitability A, CRS, European Pharmacopoeia (EP) Reference Standard

Y0002244

Aciclovir for impurity G identification, European Pharmacopoeia (EP) Reference Standard

Y0002242

Aciclovir for impurity C identification, CRS, European Pharmacopoeia (EP) Reference Standard

Código de classe de armazenamento

13 - Non Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Todd Hatchette et al.
The Pediatric infectious disease journal, 27(1), 75-77 (2007-12-29)
The authors describe an acyclovir-resistant varicella zoster virus infection in a pediatric patient after hematopoietic stem cell transplant, the use of foscarnet as salvage therapy, and review the literature to clarify the pediatric experience with foscarnet in this setting. A
Keat Choong et al.
Clinical & experimental ophthalmology, 38(3), 309-313 (2010-05-08)
Herpes simplex virus (HSV) keratitis is a common cause of ocular morbidity. Resistance to aciclovir is probably under recognized. We describe three cases of aciclovir-resistant herpes simplex virus keratitis treated with systemic foscarnet and present a review of the pharmacological
S Leflore et al.
Drug safety, 23(2), 131-142 (2000-08-17)
The objective of this article is to review and evaluate risks and benefits associated with the use of acyclovir in the treatment and prophylaxis of common manifestations of herpes simplex virus (HSV) infections in immunocompetent and immunocompromised patients. Information was
Martina Prelog et al.
Pediatric nephrology (Berlin, Germany), 26(5), 663-673 (2010-11-16)
Clear recommendations for the management of acute varicella-zoster virus (VZV) infections for cases of significant exposure and the use of prophylactic drugs after solid-organ transplantation are missing due to the lack of evidence by prospective studies. Heterogeneity in patient groups
A J Wagstaff et al.
Drugs, 47(1), 153-205 (1994-01-01)
Aciclovir (acyclovir) is a nucleoside analogue with antiviral activity in vitro against the herpes simplex viruses (HSV), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human herpesvirus 6 (HHV-6). Topical, oral or intravenous aciclovir is well established in
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica